Developer docs
API playgroundTry for free, no card

Search company profiles

Cantex Pharmaceuticals

Full company profile

uuid000cgvm

Namestring
Cantex Pharmaceuticals
Websiteurl
cantex.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Cantex Pharmaceuticals is a privately held, clinical-stage biotechnology company founded in 2002 and headquartered in Weston, United States, with a reported headcount of 1-10 employees. The company's stated mission is to harness known therapies to develop novel and safer cancer treatments, indicating a drug repositioning/reformulation strategy that leverages existing pharmacology and safety data to accelerate oncology product development. Its core products are not enumerated in available disclosures, but the positioning implies investigational oncology candidates built around repurposed or modified known agents, advanced through regulatory and clinical milestones typical of small-molecule or biologic oncology programs. The business model is consistent with a venture-backed clinical-stage biotech: revenue is generated, if at all, through licensing, milestone payments, or partnerships with larger pharmaceutical companies rather than direct product sales, and the company has raised approximately $33.6 million across six funding rounds from 2002 to 2014 from specialized biotech investors including CHL Medical Partners, Domain Associates, Research Corporation Technologies, The Aurora Funds, and Venture Academy. Leadership is concentrated in a two-person executive team — Stephen Marcus (CEO) and Gregory Johnson (COO) — and the company operates without disclosed commercial infrastructure, pricing, distribution channels, or named customers in the available data set.

Short descriptiontext

Cantex Pharmaceuticals is a privately held, clinical-stage biotechnology company founded in 2002 that develops novel and safer cancer treatments by repositioning known therapies, operating from Weston, United States with a 1-10 employee team.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWeston, United States
HQ citystring
Weston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cancer therapeutics, oncology drug development, biotechnology research, novel cancer treatments, clinical stage oncology
Industry1 code
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. The company focuses on oncology drug development, leveraging existing therapeutic modalities to create improved cancer treatments.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Novel cancer therapeutics pipeline
CategoryOncology Pharmaceuticals
Description

Development of novel and safer cancer treatments through repositioning of known therapies; intended for oncology pharmaceutical partners and ultimately cancer patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing monoclonal antibodies for cancer treatment. Operates in the same oncology drug development space with comparable mid-stage programs.

TypeBroad incumbent
Description

Established oncology biotech developing antibody-drug conjugates for cancer. A larger incumbent operating in Cantex's oncology therapeutic area with overlapping patient populations.

TypeDirect peer
Description

Clinical-stage biotech developing novel cancer therapies targeting specific tumor suppressor pathways. Comparable in scale and clinical-stage oncology development to Cantex.

TypeDirect peer
Description

Small-cap clinical-stage oncology biotech developing repurposed and novel drug candidates. Comparable to Cantex in scale, therapeutic focus, and development-stage profile.

TypeBroad incumbent
Description

Commercial-stage oncology and hematology specialty pharma. Larger, more diversified incumbent in the same oncology specialty pharmaceutical space as Cantex.

TypeBroad incumbent
Description

Established oncology specialty pharma focused on developing and commercializing novel cancer therapies. A broader, more advanced incumbent operating in Cantex's target therapeutic area.

7MEI Pharma
TypeDirect peer
Description

Oncology-focused specialty pharmaceutical company developing differentiated therapies for cancer. Operates in the same oncology specialty pharma category as Cantex with similar patient-focused positioning.

TypeBroad incumbent
Description

Specialty oncology company focused on acquiring, developing, and commercializing anti-cancer agents. A more mature oncology specialty pharma comparable in therapeutic focus.

TypeDirect peer
Description

Clinical-stage oncology company developing drugs to improve outcomes for patients with cancer. Similar size and focus on developing targeted oncology therapeutics.

TypeEmerging player
Description

Small-cap biotech focused on drug repurposing in oncology and other diseases. Directly comparable strategy to Cantex's known-therapy repositioning approach.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cantex Pharmaceuticals

Oncology Pharmaceuticalscantex.com

Cantex Pharmaceuticals is a privately held, clinical-stage biotechnology company founded in 2002 that develops novel and safer cancer treatments by repositioning known therapies, operating from Weston, United States with a 1-10 employee team.

What Cantex Pharmaceuticals does

Cantex Pharmaceuticals is a privately held, clinical-stage biotechnology company founded in 2002 and headquartered in Weston, United States, with a reported headcount of 1-10 employees. The company's stated mission is to harness known therapies to develop novel and safer cancer treatments, indicating a drug repositioning/reformulation strategy that leverages existing pharmacology and safety data to accelerate oncology product development. Its core products are not enumerated in available disclosures, but the positioning implies investigational oncology candidates built around repurposed or modified known agents, advanced through regulatory and clinical milestones typical of small-molecule or biologic oncology programs. The business model is consistent with a venture-backed clinical-stage biotech: revenue is generated, if at all, through licensing, milestone payments, or partnerships with larger pharmaceutical companies rather than direct product sales, and the company has raised approximately $33.6 million across six funding rounds from 2002 to 2014 from specialized biotech investors including CHL Medical Partners, Domain Associates, Research Corporation Technologies, The Aurora Funds, and Venture Academy. Leadership is concentrated in a two-person executive team — Stephen Marcus (CEO) and Gregory Johnson (COO) — and the company operates without disclosed commercial infrastructure, pricing, distribution channels, or named customers in the available data set.

Cantex Pharmaceuticals firmographics

Firmographics
Name
Cantex Pharmaceuticals
Website
https://cantex.com
Company type
Private
Founded year
2007
Headcount range
1–10 employees
Short description
Cantex Pharmaceuticals is a privately held, clinical-stage biotechnology company founded in 2002 that develops novel and safer cancer treatments by repositioning known therapies, operating from Weston, United States with a 1-10 employee team.
Ownership category
akta.pro rank

Cantex Pharmaceuticals industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Cancer therapeutics
  • Oncology drug development
  • Biotechnology research
  • Novel cancer treatments
  • Clinical stage oncology

Where Cantex Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Weston
HQ country
United States
HQ region
North America

Markets served

Cantex Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Cantex Pharmaceuticals product offering

Product offering

Core offering

Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. The company focuses on oncology drug development, leveraging existing therapeutic modalities to create improved cancer treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • Novel cancer therapeutics pipeline Development of novel and safer cancer treatments through repositioning of known therapies; intended for oncology pharmaceutical partners and ultimately cancer patients.

Companies that use Cantex Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Cantex Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cantex Pharmaceuticals partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights2 records

Cantex Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • MacroGenics: Clinical-stage biopharmaceutical company developing monoclonal antibodies for cancer treatment. Operates in the same oncology drug development space with comparable mid-stage programs.
  • Aprea Therapeutics: Clinical-stage biotech developing novel cancer therapies targeting specific tumor suppressor pathways. Comparable in scale and clinical-stage oncology development to Cantex.
  • Moleculin Biotech: Small-cap clinical-stage oncology biotech developing repurposed and novel drug candidates. Comparable to Cantex in scale, therapeutic focus, and development-stage profile.
  • MEI Pharma: Oncology-focused specialty pharmaceutical company developing differentiated therapies for cancer. Operates in the same oncology specialty pharma category as Cantex with similar patient-focused positioning.
  • Verastem Oncology: Clinical-stage oncology company developing drugs to improve outcomes for patients with cancer. Similar size and focus on developing targeted oncology therapeutics.

Broad incumbents

  • ImmunoGen: Established oncology biotech developing antibody-drug conjugates for cancer. A larger incumbent operating in Cantex's oncology therapeutic area with overlapping patient populations.
  • Spectrum Pharmaceuticals: Commercial-stage oncology and hematology specialty pharma. Larger, more diversified incumbent in the same oncology specialty pharmaceutical space as Cantex.
  • Puma Biotechnology: Established oncology specialty pharma focused on developing and commercializing novel cancer therapies. A broader, more advanced incumbent operating in Cantex's target therapeutic area.
  • Clovis Oncology: Specialty oncology company focused on acquiring, developing, and commercializing anti-cancer agents. A more mature oncology specialty pharma comparable in therapeutic focus.

Emerging players

  • Biovie: Small-cap biotech focused on drug repurposing in oncology and other diseases. Directly comparable strategy to Cantex's known-therapy repositioning approach.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Cantex Pharmaceuticals social profiles

Digital presence

Cantex Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cantex Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Cantex Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cantex Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cantex Pharmaceuticals

What does Cantex Pharmaceuticals do?

Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. The company focuses on oncology drug development, leveraging existing therapeutic modalities to create improved cancer treatments.

When was Cantex Pharmaceuticals founded?

Cantex Pharmaceuticals was founded in 2007. It employs 1 to 10 people.

Where is Cantex Pharmaceuticals based?

Cantex Pharmaceuticals is headquartered in Weston, United States, in the North America region.

Who are Cantex Pharmaceuticals's main competitors?

Direct peers on record are MacroGenics, Aprea Therapeutics, Moleculin Biotech, MEI Pharma and Verastem Oncology. Broad incumbents are ImmunoGen, Spectrum Pharmaceuticals, Puma Biotechnology and Clovis Oncology. Biovie is listed as an emerging player.

Does Cantex Pharmaceuticals have an API?

No public API is recorded for Cantex Pharmaceuticals.

What industry is Cantex Pharmaceuticals in?

Cantex Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCantex and Headlamp Health Forge Strategic Partnership to Accelerate Azeliragon Development via Agentic Precision Neuropsychiatry for Severe Depression and Fatigue in Patients with Multiple SclerosisCantex Pharmaceuticals and Headlamp Health announced a collaboration to apply Headlamp's Lumos AI platform to derisk and accelerate azeliragon's clinical development for severe depression and fatigue in multiple sclerosis patients. The partnership aims to identify responder phenotypes using multi-modal data, addressing symptoms affecting 40% of progressive MS patients.PR NewswireCANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCERThe FDA granted Orphan Drug Designation to Cantex Pharmaceuticals' azeliragon for treating pancreatic cancer, adding to its previous designation for glioblastoma. The designation provides seven years of marketing exclusivity from product launch, tax credits for clinical costs, exemptions from certain FDA fees, and assistance in the drug development process. Cantex has an ongoing Phase 2 clinical trial studying azeliragon in metastatic pancreatic cancer patients who are refractory to first-line treatment at several cancer treatment centers in the U.S.PR NewswireCANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCECantex Pharmaceuticals announced that its CEO Stephen Marcus will participate in the BIO CEO & Investor Conference on February 26-27, 2024 in New York City, conducting one-on-one meetings with registered investors. The company is developing azeliragon, an oral RAGE inhibitor, with ongoing Phase 2 trials in glioblastoma, brain metastasis, pancreatic cancer, and breast cancer, plus a Phase 3 trial in hospitalized pneumonia patients. Azeliragon was originally developed by vTv Therapeutics Inc., which licensed worldwide rights to Cantex, with clinical safety data from over 2,000 individuals supporting the drug's tolerability profile.PR NewswireCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMACantex Pharmaceuticals and Lenox Hill Hospital announced the initiation of a Phase 2 clinical study evaluating azeliragon, a RAGE inhibitor, in combination with radiation therapy for newly diagnosed unmethylated glioblastoma. Cantex licensed worldwide rights to azeliragon from vTv Therapeutics Inc., which originally developed the drug for Alzheimer's disease, and the company reports the drug has been well tolerated in clinical safety data from over 2,000 individuals. The study aims to address the limited treatment options for unmethylated glioblastoma, which does not respond well to chemotherapy.PR NewswireCantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain MetastasesCantex Pharmaceuticals announced the initiation of an investigator-initiated Phase 2 clinical trial combining its drug azeliragon with stereotactic radiosurgery for the treatment of brain metastases. The trial, led by Dr. Rupesh Kotecha at Miami Cancer Institute, will evaluate whether azeliragon can reduce reliance on steroids like dexamethasone while improving radiation therapy effectiveness in patients with brain metastases, which affect over 150,000 people annually. Cantex has expanded azeliragon's development across multiple cancer indications including glioblastoma, breast cancer, pancreatic cancer, and COVID-19, having licensed worldwide rights to the drug from vTv Therapeutics Inc.PR NewswireCantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast CancerCantex Pharmaceuticals announced publication of peer-reviewed research in npj Breast Cancer demonstrating that its drug azeliragon, a RAGE inhibitor, suppressed metastasis and tumor progression in triple-negative breast cancer models. The study, conducted by researchers at Georgetown University and University of Miami, showed azeliragon exerted potent anti-metastatic effects in preclinical models with a favorable safety profile from prior human trials. Cantex is expanding its collaboration with Georgetown and has ongoing clinical trials of azeliragon in multiple cancer indications.PR NewswireCANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINECantex Pharmaceuticals obtained an exclusive worldwide license from Georgetown University for intellectual property related to azeliragon as a potential treatment for cancer-treatment related cognitive decline, expanding its existing patent portfolio. Georgetown's Lombardi Comprehensive Cancer Center is currently enrolling patients in a pilot clinical trial of azeliragon in women with breast cancer receiving neoadjuvant chemotherapy, with pre-clinical studies also suggesting anti-metastatic effects in triple-negative breast cancer models. Cantex has ongoing clinical trials in metastatic pancreatic cancer, neoadjuvant breast cancer therapy, and COVID-19-related acute kidney injury, and plans to initiate phase 2 trials in newly diagnosed glioblastoma and brain metastases.PR NewswireCANTEX PHARMACEUTICALS ANNOUNCES ISSUANCE OF A PATENT FOR AZELIRAGON AS A TREATMENT OF GLIOBLASTOMACantex Pharmaceuticals announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,648,235 for treating glioblastoma with azeliragon, with claims to a method of treatment that will expire in 2042. The company also received FDA Orphan Drug Designation for azeliragon earlier this year, adding regulatory exclusivity to its intellectual property portfolio. Cantex plans to evaluate azeliragon's therapeutic effect in phase 2 glioblastoma clinical trials, while also developing the drug for brain metastasis, pancreatic cancer, breast cancer, and COVID-19.